Health CareHealth Care Equipment & Services
  • Price (GBX)1,422.21
  • Today's Change-22.79 / -1.58%
  • Shares traded395.72k
  • 1 Year change-7.71%
  • Beta0.7004
Data delayed at least 20 minutes, as of Apr 19 2021 10:43 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices. The Sports Medicine Joint Repair franchise offers surgeons a range of instruments, technologies and implants necessary to perform minimally invasive surgery of the joints, including the repair of soft tissue injuries and degenerative conditions of the knee, hip and shoulder. The AET franchise offers an array of minimally invasive surgery-enabling systems and devices. The Trauma & Extremities franchise supports healthcare professionals with solutions used by surgeons to stabilize severe fractures, correct bone deformities, treat arthritis and heal soft tissue complications.

  • Revenue in GBP (TTM)3.30bn
  • Net income in GBP323.94m
  • Incorporated1937
  • Employees17.91k
  • Location
    Smith & Nephew PLCBuilding 5, Croxley Park, Hatters LaneWATFORD WD18 8YEUnited KingdomGBR
  • Phone+44 207 401 7646
  • Fax+44 207 930 3353
  • Websitehttp://www.smith-nephew.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SN.:LSE since
Integra LifeSciences Holdings Corp-Extremity Orthopedics BusinessDeal completed29 Sep 202029 Sep 2020Deal completed-3.87%240.00m
Data delayed at least 20 minutes, as of Apr 19 2021 10:43 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Cellink AB31.68m-3.69m2.57bn215.00--12.839,046.8381.17-1.05-1.058.2542.670.23660.90193.211,718,968.00-2.81---3.00--85.48---11.86--6.36-19.400.047--------------
Elekta AB (publ)1.21bn113.22m3.71bn4.13k33.935.4616.943.073.463.4636.9121.490.55643.052.683,425,796.005.203.459.556.2441.8742.039.356.331.097.620.453754.967.726.14-9.5214.45-4.9529.20
ConvaTec Group PLC1.37bn81.35m4.12bn9.69k50.743.4118.393.010.04060.04060.68260.60270.51363.026.14141,367.703.051.473.481.6353.7853.675.943.001.724.000.481165.153.672.791,047.96--18.05--
Getinge AB2.56bn277.62m5.82bn10.82k22.493.4612.402.2811.8911.89109.4877.190.66473.285.112,756,425.007.302.239.472.9949.3947.3910.984.181.3217.340.315146.7912.27-0.2767165.0618.43-12.641.68
Amplifon SpA1.35bn87.52m6.94bn11.27k79.729.9326.705.150.4440.4446.863.560.511719.648.11138,086.403.324.634.326.1422.9754.356.506.731.176.160.661625.59-10.198.51-7.0516.634.8138.61
Demant A/S1.69bn130.59m8.54bn16.16k65.158.8634.195.074.684.6860.3434.390.66182.164.59895,636.005.198.548.2613.7971.4675.257.8411.170.648.880.5210.00-3.196.29-23.32-4.835.23--
Ambu A/S445.01m33.78m8.82bn4.20k291.8335.12158.7619.821.161.1615.299.660.78582.637.61912,347.805.978.387.1510.7063.2758.457.5910.771.055.110.439130.0826.4913.56-23.979.6632.838.83
GN Store Nord A/S1.57bn145.85m9.04bn6.53k56.7013.5833.725.779.629.62103.4340.150.80624.064.902,061,149.007.619.0810.8511.9854.2659.909.4411.290.9535108.730.530718.186.9611.64-13.8910.889.727.93
Carl Zeiss Meditec AG1.16bn112.55m11.35bn3.29k100.48----9.821.461.4614.93--------405,669.30--7.94--9.9655.9355.469.8210.17--7.06--36.70-8.495.13-23.3914.4621.815.64
Smith & Nephew plc3.30bn323.94m12.66bn17.91k39.123.3017.343.840.36820.36823.754.360.4490.84483.59184,057.104.417.915.259.5769.3972.899.8213.701.7611.020.411446.96-11.25-0.3214-25.331.794.35-5.59
Sonova Holding AG2.01bn331.66m13.41bn14.35k39.647.3627.446.676.695.2640.5736.020.51382.826.30168,611.708.5210.5710.7013.2770.8769.9216.5815.592.2633.460.446732.875.567.47-7.713.097.68--
Straumann Holding AG1.12bn71.72m15.60bn7.02k220.2116.47103.5813.935.675.6789.5475.810.57741.764.24203,257.503.7413.464.6516.2572.2275.296.4718.552.477.610.365234.41-10.6712.29-70.225.2518.467.53
Coloplast A/S2.16bn494.05m22.93bn12.50k50.0036.6538.7010.6019.8819.8887.0427.121.322.886.301,494,327.0030.1331.5761.8354.5767.8867.8822.8422.680.566617.460.44789.513.375.928.3736.098.587.57
Data as of Apr 19 2021. Currency figures normalised to Smith & Nephew PLC's reporting currency: UK Pound GBX

Institutional shareholders

24.62%Per cent of shares held by top holders
HolderShares% Held
Wellington Management Co. LLPas of 31 Dec 202042.67m4.85%
WCM Investment Management LLCas of 03 Mar 202033.98m3.87%
BlackRock Fund Advisorsas of 12 Feb 202124.77m2.82%
The Vanguard Group, Inc.as of 01 Apr 202122.18m2.52%
Norges Bank Investment Managementas of 01 Apr 202119.99m2.27%
Walter Scott & Partners Ltd.as of 01 Apr 202118.91m2.15%
Rathbone Investment Management Ltd.as of 01 Apr 202116.14m1.84%
Fidelity Management & Research Co. LLCas of 01 Apr 202113.29m1.51%
State Street Global Advisors Ltd.as of 01 Apr 202112.78m1.45%
Schroder Investment Management Ltd.as of 01 Apr 202111.71m1.33%
More ▼
Data from 31 Dec 2020 - 15 Apr 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.